Continuous directed evolution using engineered human B cell lines
Abstract The B cells of the human immune system have evolved somatic hypermutation (SHM) mechanisms that introduce mutations at the immunoglobulin genomic loci at a significantly higher frequency than the rest of the genome thereby allowing them to evolve antibody sequences without compromising fitness due to genome-wide mutations. Inspired by these observations, here we develop a continuous directed evolution platform in human B cell lines (CODE-HB) that repurposes the SHM mechanisms to a stable, non-immunoglobulin genomic locus of the human B cell lines to continuously evolve cytosolic and surface displayed proteins with a broad mutational spectrum comprising of substitutions, deletions and insertions. Using our human B cell surface display platform and CODE-HB, we evolve neutralizing antibodies targeting avian influenza and escape variants of influenza. Given the modularity and simplicity of CODE-HB, we anticipate that this platform can be used for rapidly evolving biotechnologically relevant biomolecules directly in human cells.
Authors
- Jordan Quenneville (ORCID: https://orcid.org/0009-0000-1498-6614)
- Jenna J. Guthmiller (ORCID: https://orcid.org/0000-0001-7566-3536)
- Angad P. Mehta (ORCID: https://orcid.org/0000-0003-2585-8268)
- Sarah Leach (ORCID: https://orcid.org/0000-0002-1872-6446)
- Hui Xu (ORCID: https://orcid.org/0000-0002-1773-3978)
- Graeme Lindsey
Institutions
- University of Illinois Urbana-Champaign (US)
- Cancer Center at Illinois (US)
- Carl R. Woese Institute for Genomic Biology (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-06
- DOI
- https://doi.org/10.1038/s41467-026-79127-y
- Citations
- 2
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 2.12
Funders
- Howard Hughes Medical Institute
- Ono Pharma Foundation
- University of Illinois at Urbana-Champaign